key: cord-0871894-y9uutr12
authors: Chakraborty, Uddalak; Hati, Arkapravo; Chandra, Atanu
title: Letter and response to letter: Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication
date: 2021-12-23
journal: Diabetes Metab Syndr
DOI: 10.1016/j.dsx.2021.102370
sha: cab34bbaf1cd0da124986557ef16350e0a6ab8d4
doc_id: 871894
cord_uid: y9uutr12

nan

Dear Editor, It gives us immense pleasure to find out that our article has been read with such interest and you have received a letter NINDS, Cornblath, Asbury, or Brighton criteria for diagnosing COVID-19 associated Guillain-Barre syndrome?

We hereby would try to answer the queries raised by the authors of the above-mentioned letter and wholeheartedly accept the limitations of our study which have been pointed out to an extent. The Asbury criteria have been used in our series. We totally agree that Brighton criteria is globally acceptable standardized criteria for diagnosis of Guillain-Barre syndrome(GBS) with 4 levels of diagnostic certainty 1 ; however considering bedside management of patients amidst the COVID-19 pandemic with overburdened healthcare system, Asbury criteria may be a simple tool for diagnosis of GBS and initiate treatment at the earliest when electrodiagnostic studies and CSF analysis is not available round the clock in resource limited setups.

We totally agree with the statement that GBS should also be differentiated from neuronopathy, polyneuropathy, plexopathy, compression neuropathy apart from critical illness neuropathy and myopathy, but in patients with severe COVID-19, prolonged stays in intensive care unit may lead to critical illness neuropathy and myopathy which may mask an underlying GBS.

The death of AIDP-2 patient occurred within a few hours of admission due to a sudden cardiac arrest in a background of severe ARDS (PaO2/FiO2 <100), and we were unable to resuscitate the patient despite our best efforts. The cause of death maybe due to severe ARDS attributable to COVID-19, but since autopsy was not performed, it is difficult to comment on the exact cause of death. The AMSAN-1 patient may have succumbed to a fatal ventricular tachycardia in the background of multiorgan dysfunction due to severe bacterial sepsis (CRP-232mg/dl, procalcitonin-7.56 ng/ml) We were unable to resuscitate him and it is difficult to comment on the exact cause of death in absence of an autopsy.

Descending pattern of weakness also left us baffled. We are grateful to the authors of the letter for pointing out a possible explanation of autoimmune plexitis.

We hereby apologize for the typographical error in Table 2 , where AIDP-2 has been mentioned incorrectly as discharged instead of succumbed and data of AIDP-2 have been swapped with AIDP-3 in this table.

Among the patients with dysautonomia, in the AIDP patient, marked variations in heart rate ranging from intermittent tachycardia (160-170/min) to bradycardia (<60/min) at times indicated an underlying cardiovagal dysfunction. Heart rate variability (HRV) with respiration (E/I) in this; patient was 17 beats/min. Among the patients with AMAN and AMSAN, dysautonomia manifested as severe fluctuations in blood pressure and sudomotor dysfunction in the form of excessive sweating at times. J o u r n a l P r e -p r o o f AMAN patients were described based on the electrodiagnostic findings, dysautonomia may be seen in axonal variants of GBS. 2 According to the Asbury criteria fever at onset of neuritic symptoms has been mentioned as a variant (not ranked) however the presence of fever at onset does not rule out the diagnosis of GBS. 3 Moreover, the febrile patients had variable latency from onset of fever to neuropathic weakness.

Respiratory insufficiency in the ventilated patients may be attributable to both COVID-19 and GBS, however the AIDP patient with the need of invasive ventilation had severe ARDS due to COVID-19, which necessitated invasive ventilation. The AMSAN patient had developed severe type I respiratory failure and hence required invasive ventilation, likely due to GBS. The AMAN patients had severe respiratory failure due to GBS and also had moderate to severe COVID-19 which necessitated invasive ventilation, hence both maybe contributory. We again apologize for the typographical error from our side, where data of AIDP-3 has been swapped with data of AIDP-2 in Table 2 , where the patient with EGRIS-6 was ventilated but succumbed to sudden cardiac arrest despite our best efforts.

On 6 months followup, all the patients who were discharged were alive and their mRC sum score have considerably improved compared to discharge.

We acknowledge the fact that our study has several limitations and Brighton criteria should have been the ideal tool for diagnosing GBS. However, we are extremely grateful to the authors of the above-mentioned letter because our efforts to give a comprehensive overview on 8 cases of COVID-19 associated GBS from presentation to outcome amidst the pandemic has been read with such interest.

Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria

Autonomic involvement in Guillain-Barré syndrome: an update

Assessment of current diagnostic criteria for Guillain-Barré syndrome

J o u r n a l P r e -p r o o f